BioMimetic Therapeutics, Inc. to Highlight Corporate Activities at BIO InvestorForum 2007
Franklin, Tenn. – October 5, 2007 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that Dr. Samuel E. Lynch, president and CEO, will provide an update of corporate activities at the BIO InvestorForum 2007. The presentation will take place in the Twin Peaks South Room of the Palace Hotel in San Francisco on Wednesday, October 10 at 3:45 p.m. Pacific Time.
A live audio webcast of the presentation will be available at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BMTI&item_id=1642645 and on the Company's website at www.biomimetics.com. The webcast will be accessible for a period of at least 30 days.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, periodontal, spine and sports injury applications. BioMimetic received marketing approval from the FDA for its first product, GEM 21S®, as a grafting material for bone and periodontal regeneration following completion of human clinical trials, which demonstrated the safety and efficacy of its platform technology in this indication. Additionally, the Company has clinical trials ongoing with its product candidates GEM OS®1 and GEM OS®2 in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the arm. The Company's product and lead product candidates all combine recombinant protein therapeutics with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, associate director of corporate communications, at 615-236-4419.
###
Back to Headlines |
